<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8DB38BE9-A921-41DE-B6EC-A43C3BB0EA11"><gtr:id>8DB38BE9-A921-41DE-B6EC-A43C3BB0EA11</gtr:id><gtr:name>Vietnam National University (VNU)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EC1D7232-9B00-44B3-BBAA-ACB3381663DD"><gtr:id>EC1D7232-9B00-44B3-BBAA-ACB3381663DD</gtr:id><gtr:name>Blueberry Therapeutics</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7E833A22-66FB-41DB-BB4E-283D08AF9A6E"><gtr:id>7E833A22-66FB-41DB-BB4E-283D08AF9A6E</gtr:id><gtr:name>Janssen Research &amp; Development</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F8302422-55CA-4DFF-817B-9EBECA831882"><gtr:id>F8302422-55CA-4DFF-817B-9EBECA831882</gtr:id><gtr:name>The Global Alliance for TB Drug Development</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FFDE1B31-6FE1-4451-8471-23644FFEB793"><gtr:id>FFDE1B31-6FE1-4451-8471-23644FFEB793</gtr:id><gtr:name>Vietnam National Lung Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/CCCAF38E-905A-4201-A354-906F1BC43502"><gtr:id>CCCAF38E-905A-4201-A354-906F1BC43502</gtr:id><gtr:name>Shanghai Institute of Organic Chemistry (SIOC)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/035E7435-BA5D-4775-9837-6EC2C8323A30"><gtr:id>035E7435-BA5D-4775-9837-6EC2C8323A30</gtr:id><gtr:name>Guangdong University of Technology</gtr:name><gtr:address><gtr:line1>729 East Dongfeng Road</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FC48271D-57EB-4AB8-ACF9-B104EB984FA6"><gtr:id>FC48271D-57EB-4AB8-ACF9-B104EB984FA6</gtr:id><gtr:name>Vietnam Academy of Science and Technology</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3ED60B49-9C2B-4D71-B644-96CCC7F10194"><gtr:id>3ED60B49-9C2B-4D71-B644-96CCC7F10194</gtr:id><gtr:name>Liverpool School of Tropical Medicine</gtr:name><gtr:department>Molecular and Biochemical Parasitology</gtr:department><gtr:address><gtr:line1>School Of Tropical Medicine</gtr:line1><gtr:line2>Pembroke Place</gtr:line2><gtr:postCode>L3 5QA</gtr:postCode><gtr:region>North West</gtr:region></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3ED60B49-9C2B-4D71-B644-96CCC7F10194"><gtr:id>3ED60B49-9C2B-4D71-B644-96CCC7F10194</gtr:id><gtr:name>Liverpool School of Tropical Medicine</gtr:name><gtr:address><gtr:line1>School Of Tropical Medicine</gtr:line1><gtr:line2>Pembroke Place</gtr:line2><gtr:postCode>L3 5QA</gtr:postCode><gtr:region>North West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8DB38BE9-A921-41DE-B6EC-A43C3BB0EA11"><gtr:id>8DB38BE9-A921-41DE-B6EC-A43C3BB0EA11</gtr:id><gtr:name>Vietnam National University (VNU)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EC1D7232-9B00-44B3-BBAA-ACB3381663DD"><gtr:id>EC1D7232-9B00-44B3-BBAA-ACB3381663DD</gtr:id><gtr:name>Blueberry Therapeutics</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7E833A22-66FB-41DB-BB4E-283D08AF9A6E"><gtr:id>7E833A22-66FB-41DB-BB4E-283D08AF9A6E</gtr:id><gtr:name>Janssen Research &amp; Development</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F8302422-55CA-4DFF-817B-9EBECA831882"><gtr:id>F8302422-55CA-4DFF-817B-9EBECA831882</gtr:id><gtr:name>The Global Alliance for TB Drug Development</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FFDE1B31-6FE1-4451-8471-23644FFEB793"><gtr:id>FFDE1B31-6FE1-4451-8471-23644FFEB793</gtr:id><gtr:name>Vietnam National Lung Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CCCAF38E-905A-4201-A354-906F1BC43502"><gtr:id>CCCAF38E-905A-4201-A354-906F1BC43502</gtr:id><gtr:name>Shanghai Institute of Organic Chemistry (SIOC)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/035E7435-BA5D-4775-9837-6EC2C8323A30"><gtr:id>035E7435-BA5D-4775-9837-6EC2C8323A30</gtr:id><gtr:name>Guangdong University of Technology</gtr:name><gtr:address><gtr:line1>729 East Dongfeng Road</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FC48271D-57EB-4AB8-ACF9-B104EB984FA6"><gtr:id>FC48271D-57EB-4AB8-ACF9-B104EB984FA6</gtr:id><gtr:name>Vietnam Academy of Science and Technology</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/A181FD3D-F540-4D3B-9D83-514FFD53DC26"><gtr:id>A181FD3D-F540-4D3B-9D83-514FFD53DC26</gtr:id><gtr:firstName>Neil</gtr:firstName><gtr:surname>Berry</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C943CC76-B042-406D-A1CB-E97710EF626F"><gtr:id>C943CC76-B042-406D-A1CB-E97710EF626F</gtr:id><gtr:firstName>Giancarlo</gtr:firstName><gtr:otherNames>Augusto</gtr:otherNames><gtr:surname>Biagini</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/35C0CE50-61C8-4951-A6BD-C121ABC82F8E"><gtr:id>35C0CE50-61C8-4951-A6BD-C121ABC82F8E</gtr:id><gtr:firstName>Stephen</gtr:firstName><gtr:surname>Ward</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/375C4076-CC65-4A66-A0A7-25F6C7C73E03"><gtr:id>375C4076-CC65-4A66-A0A7-25F6C7C73E03</gtr:id><gtr:firstName>Paul</gtr:firstName><gtr:surname>O'Neill</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/DC218283-824E-45BD-940C-8C9621994B08"><gtr:id>DC218283-824E-45BD-940C-8C9621994B08</gtr:id><gtr:firstName>Nick</gtr:firstName><gtr:surname>Cammack</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G1002586"><gtr:id>B87F2C5F-F0A6-4FA1-87E0-E4FB32F722E2</gtr:id><gtr:title>LEAD SERIES DEVELOPMENT &amp;amp; OPTIMISATION OF A NEW DRUG AGAINST ACTIVE AND LATENT TUBERCULOSIS</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G1002586</gtr:grantReference><gtr:abstractText>According to the most recent estimates, TB killed 1.7 million people in 2009 (approximately a death every 20seconds). Treatment for TB relies on drugs developed some 40 years ago. Unfortunately these drugs are not very good as they require long treatment regimes (6-9 months) and often they do not work due to the ability of the TB bug to develop resistance. Using a novel strategy we propose to develop a new drug that will be able to kill all of the TB bugs quickly including the resistant ones. To develop this drug we have partnered up with industry (GSK pharmaceuticals) and will use industry-like development and management methods. If we succeed in this 2 year project, we are confident that we can secure future funding from the TB Alliance so that we can eventually register our new drug within the next five or six years.</gtr:abstractText><gtr:technicalSummary>A major failure of current tuberculosis (TB) therapies is that they predominantly target replicating Mycobacterium tuberculosis (Mtb) but are unable to sterilize slow growing (dormant) Mtb, leading to protracted treatment regimes and the development of drug resistance. We propose to generate a new drug against TB that is able to mitigate the shortcomings of current therapies, leading to improved treatment outcomes. Our strategy is to target the Mtb respiratory chain, specifically NADH:menaquinone oxidoreductase (ndh). This target is essential for the survival of replicating, dormant and drug resistant Mtb, and it is absent in humans. Over the past 2 years we have successfully progressed from target validation/hit identification to the discovery of novel potent (nM) inhibitors of ndh with corresponding potent (nM) in vitro sterilization activity against replicating and dormant Mtb. This proposed schedule of work is to advance these early leads through to late lead development and optimization in readiness for candidate selection.</gtr:technicalSummary><gtr:fund><gtr:end>2014-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1022084</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Blueberry Therapeutics</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Novel antibiotic nano formulations</gtr:description><gtr:id>2200BE60-C5E4-48A9-A333-353A977769CD</gtr:id><gtr:impact>none yet</gtr:impact><gtr:outcomeId>56ddadb0dfcfd8.01285821-1</gtr:outcomeId><gtr:partnerContribution>nano-formulation expertise and materials</gtr:partnerContribution><gtr:piContribution>Imaging and PK-PD platform to screen novel antibiotic formulations against Salmonella</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Shanghai Institute of Organic Chemistry (SIOC)</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:description>Shanghai Institute of Organic Chemistry (SIOC.)</gtr:description><gtr:id>4C600ABF-3592-46E3-A665-51EB69DC4B1C</gtr:id><gtr:impact>Shanghai Institute of Organic Chemistry (SIOC.) and the Liverpool groups have begun a collaboration in drug discovery programs. SIOC is providing chemical compounds for screening and helping with complex synthetic routes whilst the Liverpool team is providing testing against TB, malaria and NTDs as well as full pre-clinical support (e.g. pharmacology, biology, med chem), to and clinical.</gtr:impact><gtr:outcomeId>545cee56bbd5b5.30539922-1</gtr:outcomeId><gtr:partnerContribution>Shanghai Institute of Organic Chemistry (SIOC.) and the Liverpool groups have begun a collaboration in drug discovery programs. SIOC is providing chemical compounds for screening and helping with complex synthetic routes whilst the Liverpool team is providing testing against TB, malaria and NTDs as well as full pre-clinical support (e.g. pharmacology, biology, med chem), to and clinical.</gtr:partnerContribution><gtr:piContribution>Shanghai Institute of Organic Chemistry (SIOC.) and the Liverpool groups have begun a collaboration in drug discovery programs. SIOC is providing chemical compounds for screening and helping with complex synthetic routes whilst the Liverpool team is providing testing against TB, malaria and NTDs as well as full pre-clinical support (e.g. pharmacology, biology, med chem), to and clinical.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Vietnam National University (VNU)</gtr:collaboratingOrganisation><gtr:country>Vietnam, Socialist Republic of</gtr:country><gtr:description>Using pharmacokinetic - pharmacodynamic analyses to select optimal dosing for non-MDR pulmonary TB treatment failure patients in Vietnam</gtr:description><gtr:id>D8BC18C1-A44D-4BFA-8528-0A6992CB886D</gtr:id><gtr:impact>Uk researchers have been involved in training VN researchers in the UK and Ethics applications have been submitted and approved for the clinical study due to begin in May 2017.</gtr:impact><gtr:outcomeId>58c6903d060f08.78643982-2</gtr:outcomeId><gtr:partnerContribution>The collaboration is between the UK and a number of institutions in VN (listed above). The project is specifically trying to address the underlying reasons for TB treatment failures but in terms of training, UK researchers are providing training in Pharmacology, specifically pharmacokinetics and PK-PD modelling, addressing a specific expertise gap in VN and the National TB Programme.</gtr:partnerContribution><gtr:piContribution>This collaboration has been funded via the MRC-Newton call in collaboration with the MOST ministry of Vietnam</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Vietnam Academy of Science and Technology</gtr:collaboratingOrganisation><gtr:country>Vietnam, Socialist Republic of</gtr:country><gtr:description>Using pharmacokinetic - pharmacodynamic analyses to select optimal dosing for non-MDR pulmonary TB treatment failure patients in Vietnam</gtr:description><gtr:id>77B1CD77-9EAC-42CC-AF8B-A06C69CBC1D5</gtr:id><gtr:impact>Uk researchers have been involved in training VN researchers in the UK and Ethics applications have been submitted and approved for the clinical study due to begin in May 2017.</gtr:impact><gtr:outcomeId>58c6903d060f08.78643982-3</gtr:outcomeId><gtr:partnerContribution>The collaboration is between the UK and a number of institutions in VN (listed above). The project is specifically trying to address the underlying reasons for TB treatment failures but in terms of training, UK researchers are providing training in Pharmacology, specifically pharmacokinetics and PK-PD modelling, addressing a specific expertise gap in VN and the National TB Programme.</gtr:partnerContribution><gtr:piContribution>This collaboration has been funded via the MRC-Newton call in collaboration with the MOST ministry of Vietnam</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Global Alliance for TB Drug Development</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>TB Alliance</gtr:description><gtr:id>B0296C0C-0C07-4B9E-9BB3-11DDFE1CA91E</gtr:id><gtr:impact>TBAlliance are providing support in the way of in vivo PK and TB in vivo drug efficacy models (rodent acute model)

If successful this will form the basis of a more extensive drug development programme</gtr:impact><gtr:outcomeId>545ce90db19483.85570640-1</gtr:outcomeId><gtr:partnerContribution>TBAlliance have conducted in vivo PK studies on our lead compounds and we will shortly be conducting in vivo drug efficacy experiments using their TB drug development network

If successful this will form the basis of a more extensive drug development programme</gtr:partnerContribution><gtr:piContribution>We have developed inhibitors via the MRC funded project that are at lead stage - these are being tested presently. We are also in discussions with TBA regarding our high content imaging platform, the development of which is supported via a MRC CiC award</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Guangdong University of Technology</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:description>Guangdong University of Technology, China (GDUT)</gtr:description><gtr:id>E8892AF8-4338-4524-84A0-055FBCB867F9</gtr:id><gtr:impact>Compounds have been synthesised and teaching programs are being developed by the consortium</gtr:impact><gtr:outcomeId>545ced103a3f92.62616490-1</gtr:outcomeId><gtr:partnerContribution>We have set up a Liverpool-Guangdong Drug Discovery Consortium. The consortium, made up of LSTM, University of Liverpool (UoL), Department of Chemistry and the Department of Pharmacy Engineering, Guangdong University of Technology, China (GDUT), is focussed on the development of new drug therapies for the treatment of TB, Malaria and other infectious diseases. A new laboratory has been opened known as the &amp;quot; Liverpool-Guangzhou drug discovery joint laboratory&amp;quot;, located at GDUT. The laboratory will accommodate a drug discovery team made up of staff and students from GDUT and other parts of China. Pre-clinical projects targeting TB as well as malaria and NTD infections will be co-developed by the consortium.</gtr:partnerContribution><gtr:piContribution>We have set up a Liverpool-Guangdong Drug Discovery Consortium. The consortium, made up of LSTM, University of Liverpool (UoL), Department of Chemistry and the Department of Pharmacy Engineering, Guangdong University of Technology, China (GDUT), is focussed on the development of new drug therapies for the treatment of TB, Malaria and other infectious diseases. A new laboratory has been opened known as the &amp;quot; Liverpool-Guangzhou drug discovery joint laboratory&amp;quot;, located at GDUT. The laboratory will accommodate a drug discovery team made up of staff and students from GDUT and other parts of China. Pre-clinical projects targeting TB as well as malaria and NTD infections will be co-developed by the consortium.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Vietnam National Lung Hospital</gtr:collaboratingOrganisation><gtr:country>Vietnam, Socialist Republic of</gtr:country><gtr:description>Using pharmacokinetic - pharmacodynamic analyses to select optimal dosing for non-MDR pulmonary TB treatment failure patients in Vietnam</gtr:description><gtr:id>8B752724-6B19-43B5-973D-6451F5BE0715</gtr:id><gtr:impact>Uk researchers have been involved in training VN researchers in the UK and Ethics applications have been submitted and approved for the clinical study due to begin in May 2017.</gtr:impact><gtr:outcomeId>58c6903d060f08.78643982-1</gtr:outcomeId><gtr:partnerContribution>The collaboration is between the UK and a number of institutions in VN (listed above). The project is specifically trying to address the underlying reasons for TB treatment failures but in terms of training, UK researchers are providing training in Pharmacology, specifically pharmacokinetics and PK-PD modelling, addressing a specific expertise gap in VN and the National TB Programme.</gtr:partnerContribution><gtr:piContribution>This collaboration has been funded via the MRC-Newton call in collaboration with the MOST ministry of Vietnam</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>AstraZeneca</gtr:description><gtr:id>2305FC07-8101-4662-B811-83ABB2F0A092</gtr:id><gtr:impact>multidisciplinary collaboration. The project is still on going and only hit molecules identified thus far. Lead series will be identified in the next 12 months.</gtr:impact><gtr:outcomeId>V7ZVJV3TvEb-1</gtr:outcomeId><gtr:partnerContribution>AstraZeneca are providing starting points (hits) for testing against TB and malaria and they are also providing HTS expertise, chemoinformatics and ADMET screening. AZ collaborating partners are based both in the UK and India. Aspects of this collaboration are also within the WIPO (World intellectual Property Organisation) umbrella.</gtr:partnerContribution><gtr:piContribution>A collaboration is underway for both malaria and TB drug discovery. LSTM research team are providing in vitro and in vivo PD and PK models and expertise in drug discovery for these specific diseases. Aspects of this collaboration are also within the WIPO (World intellectual Property Organisation) umbrella.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Janssen Research &amp; Development</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Drug Discovery Project to develop combination partners targeting the respiratory chain of Mycobacterium tuberculosis</gtr:description><gtr:id>6EDA0AFE-A52A-4A57-B0F8-5805F25EF2D3</gtr:id><gtr:impact>No outputs as yet</gtr:impact><gtr:outcomeId>56ddabeac87457.42273105-1</gtr:outcomeId><gtr:partnerContribution>Janssen have provided Materials e.g. bedaquiline. Discussions are taking place for a formal partnership and funding by Janssen of project as well as exclusive licensing of LSTM IP to Janssen.</gtr:partnerContribution><gtr:piContribution>Novel strategy to improve the efficacy of bedaquiline and NCE</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>Spain, Kingdom of</gtr:country><gtr:department>Tres Cantos Medicines Development Campus</gtr:department><gtr:description>Collaboration with GSK</gtr:description><gtr:id>F1E0E355-258F-431A-98D2-FB2CFCBCD822</gtr:id><gtr:impact>The team has generated early leads targeting a novel biological target in M. tuberculosis</gtr:impact><gtr:outcomeId>PyYcHEhgYmA-1</gtr:outcomeId><gtr:partnerContribution>The GSK team is part of the product development team and specifically carries out in vivo antitubercular testing in their acute and chronic models</gtr:partnerContribution><gtr:piContribution>The Liverpool research team undertakes early phase drug discovery of new anti-tuberculosis compounds which includes HTS screening, predictive in vitro models, medicinal chemistry, in vitro ADMET and in vivo DMPK</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Manchester Science Festival</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>41744EFE-BD63-46B4-8708-F4637A73123D</gtr:id><gtr:impact>October 2013 Manchester Science Festival at MOSI took part in 'I'm a scientist, talk to me' with Science Grrl. Over 100,000 attendees for the festival. Spoke to children and adults, mainly 5 -17 years old.

not known</gtr:impact><gtr:outcomeId>DtVGbyE88Rq</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Science Festival - Lancashire</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>C3C80B90-B78D-42BB-835D-80B18961BC41</gtr:id><gtr:impact>June 2013 the Lancashire Science Festival at UCLAN took part in 'I'm a scientist, talk to me' with Science Grrl. 2500 attendees of all ages, spoke to mainly children aged 4-12.

not known</gtr:impact><gtr:outcomeId>EkW4bdBX36L</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:url>http://sciencegrrl.co.uk/lancashire-science-festival/</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Press Release - New Centre for Drugs and Diagnostics</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>286BFEF9-4CF0-4CED-972A-B68C9DD0CCD7</gtr:id><gtr:impact>Press release of the new LSTM Centre for Drugs and Diagnostics

A breakfast launch meeting was hosted at the British Society for Parasitology in Nest Gardens, 2013 with 20+ representatives of Small-Medium Enterprises</gtr:impact><gtr:outcomeId>Y7gt9dboZAA</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url> http://www.lstmliverpool.ac.uk/about-lstm/news-and-media/latest-news/launch-of-the-lstm-research-centre-for-drugs-and-diagnostics</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School Visit (Chester)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>45CECB53-B282-4FE0-B572-8D4C4300B61F</gtr:id><gtr:impact>60 children attended - this was a presentation by me and interactive sessions with the children and teachers.

My visit was discussed by the headmaster at the whole school level and was reported to governors and in local news.</gtr:impact><gtr:outcomeId>AwgNJLDuJJd</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>478278</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:department>Seventh Framework Programme (FP7)</gtr:department><gtr:description>IMI EU FP7 &amp;quot;Model-based preclinical development of anti-tuberculosis drug combinations&amp;quot;</gtr:description><gtr:end>2017-04-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>848CF05D-681A-4324-B72D-5ECE9994DDA2</gtr:id><gtr:outcomeId>CaYvCz3Fiuu</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>399449</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC newton Vietnam</gtr:description><gtr:end>2018-07-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/N028376/1	</gtr:fundingRef><gtr:id>955A872B-7ED4-4096-AB55-B7E4103D098D</gtr:id><gtr:outcomeId>58245129034831.16513195</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>98000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Redx Pharma PLC</gtr:description><gtr:end>2022-07-02</gtr:end><gtr:fundingOrg>Redx Pharma Plc</gtr:fundingOrg><gtr:id>EABE3FE2-5E3A-4DDE-AA86-896F9C965DF5</gtr:id><gtr:outcomeId>5825cbb78fd365.28263563</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2016-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>600000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust - Multi-User Equipment Grant</gtr:description><gtr:end>2019-10-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>A57A44C3-19FE-4C42-AF4E-145CECA5F573</gtr:id><gtr:outcomeId>545cf1568f8d92.05782488</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-11-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Novel design of Combination Therapy for Tuberculosis drugs based on the inhibition of respiratory inhibitors.

TheUK patent application has been submitted and the number is 1522232.6
The patent has been submitted and Janssen Pharmaceutica are interested in an exclusive licence - discussion are underway</gtr:description><gtr:grantRef>G1002586</gtr:grantRef><gtr:id>4173196B-90AC-47E0-9795-AB1CBBBAFBD1</gtr:id><gtr:impact>The patent has been submitted and Janssen Pharmaceutica are interested in an exclusive licence</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>56dda438aec909.61067804</gtr:outcomeId><gtr:patentId>UK Patent application 1522232.6</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Combination Therapy</gtr:title></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>? UK management committee member for COST Action CM1307, 'Targeted chemotherapy towards diseases caused by endoparasites&amp;quot; - 2014- to date</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>3C06EFC6-8FE2-4075-92BE-1A4E95CA8477</gtr:id><gtr:outcomeId>56ddaeb04727c0.83647859</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type><gtr:url>http://www.costcm1307.org/CM1307/Home.html</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Steering committee for an EU TB drug discovery consortium</gtr:description><gtr:geographicReach>Asia</gtr:geographicReach><gtr:id>D4078BE0-9B98-4945-A371-EFA02ABA04DD</gtr:id><gtr:outcomeId>Hfo78JfxWY5</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>Lead series identification. The series has activity against MDR TB and currently being assessed for in vivo efficacy</gtr:description><gtr:id>BAA3530C-E51B-4FBC-9D26-EA894ECBDE81</gtr:id><gtr:impact>Lead series identification. The series has activity against MDR TB and currently being assessed for in vivo efficacy. The lead series have a novel mode of action.</gtr:impact><gtr:outcomeId>G8wUyhdZJQ6</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>New Drug against TB</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2010</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Multi-User Equipment Grant entitled 'Supporting excellence in basic and clinical research: A flow cytometry/sorting and cell imaging platform for the genotypic and phenotypic analysis of Hazard Group 3 pathogens'

We have set up to our knowledge the first dedicated HG3 imaging facility, able to sort and image HG3 pathogens, e.g. TB and HIV</gtr:description><gtr:id>30D30A84-93CD-40CE-93DE-9546593335F1</gtr:id><gtr:impact>It has just been set up, impact will be described next year</gtr:impact><gtr:outcomeId>545cf60f2a3ba6.86792804</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Multi-User Equipment Grant entitled 'Supporting excellence in basic and clinical research: A flow cytometry/sorting and cell imaging platform for the genotypic and phenotypic analysis of Hazard Group 3 pathogens'</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have set up a high-content imaging platform for the measurement of intracellular M. tuberculosis. A clinically significant sub-population of Mtb is found inside host cells, e.g. macrophages. Using our HC platform we are now able to identify drugs that are active against this sub-population. 

This platform will have significant utility in identifying drugs that can treat drug persistent Mtb.</gtr:description><gtr:id>5C4FDB00-C1EC-49B3-84F0-9B933578E26B</gtr:id><gtr:impact>This system is currently being evaluated as an improved in vitro system for the clinical prediction of drug activity. If found to be predictive, this system is likely to be incorporated into drug discovery pipelines used by industry and academia.</gtr:impact><gtr:outcomeId>aYfDGjonJtr</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>High-content imaging platform for intracellular M. tuberculosis</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have generated a stable GFP-transformed Mtb. This allows the real-time monitoring of Mtb using fluorescence-based technologies.</gtr:description><gtr:id>72212FE2-7530-46C1-8C82-8CE5AAAEBA2F</gtr:id><gtr:impact>The GFP-tagged Mtb allows the investigator to &amp;quot;follow&amp;quot; the Mtb infection, replication and viability in a variety of model systems, e.g. intracellular systems, whole blood assay etc.</gtr:impact><gtr:outcomeId>rDFSq18RGLT</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>GFP-Mycobacterium tuberculosis</gtr:title><gtr:type>Cell line</gtr:type><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>89AF1C63-4376-41E7-B9C9-19F114682195</gtr:id><gtr:title>Rapid kill of malaria parasites by artemisinin and semi-synthetic endoperoxides involves ROS-dependent depolarization of the membrane potential.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d5e218f46ddd0cc184cc414306d19603"><gtr:id>d5e218f46ddd0cc184cc414306d19603</gtr:id><gtr:otherNames>Antoine T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>545ce4ab3a4295.17639886</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>01A3F921-D7B9-451B-A327-F3E9DB67606A</gtr:id><gtr:title>The proliferating cell hypothesis: a metabolic framework for Plasmodium growth and development.</gtr:title><gtr:parentPublicationTitle>Trends in parasitology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d436bdab223cade1091ca9ed24b61485"><gtr:id>d436bdab223cade1091ca9ed24b61485</gtr:id><gtr:otherNames>Salcedo-Sora JE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1471-4922</gtr:issn><gtr:outcomeId>545ce4797b6773.55638280</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E630A66A-A0E1-47C8-A11C-0EB606651074</gtr:id><gtr:title>Antimalarial 4(1H)-pyridones bind to the Qi site of cytochrome bc1.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9e5db9282245589c619bb56f39465c7d"><gtr:id>9e5db9282245589c619bb56f39465c7d</gtr:id><gtr:otherNames>Capper MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>56dda54184d5a4.92437358</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>858FEDCF-E034-486E-A3E3-CB9E8F5D2A4C</gtr:id><gtr:title>Pharmacokinetic-Pharmacodynamic modelling of intracellular Mycobacterium tuberculosis growth and kill rates is predictive of clinical treatment duration.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1e3511efcc710829c2226c3891942d74"><gtr:id>1e3511efcc710829c2226c3891942d74</gtr:id><gtr:otherNames>Aljayyoussi G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5a361b24901a41.23135758</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>950BB7B6-B069-4383-A71F-1E20FEF185CC</gtr:id><gtr:title>Targeting the mitochondrial electron transport chain of Plasmodium falciparum: new strategies towards the development of improved antimalarials for the elimination era.</gtr:title><gtr:parentPublicationTitle>Future medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0f0f08f38aed1db3df1b22aebf96ff04"><gtr:id>0f0f08f38aed1db3df1b22aebf96ff04</gtr:id><gtr:otherNames>Nixon GL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1756-8919</gtr:issn><gtr:outcomeId>doi_14692_fmc_13_121</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>886D0836-0F6E-415C-8915-66DB3C84E181</gtr:id><gtr:title>Novel inhibitors of the Plasmodium falciparum electron transport chain.</gtr:title><gtr:parentPublicationTitle>Parasitology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/001da32001d5fbced797c03667da79c5"><gtr:id>001da32001d5fbced797c03667da79c5</gtr:id><gtr:otherNames>Stocks PA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0031-1820</gtr:issn><gtr:outcomeId>545ce4dea57cb8.50448986</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4662362C-4816-41FB-AE1E-C1E32D781969</gtr:id><gtr:title>Antimalarial pharmacology and therapeutics of atovaquone.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0f0f08f38aed1db3df1b22aebf96ff04"><gtr:id>0f0f08f38aed1db3df1b22aebf96ff04</gtr:id><gtr:otherNames>Nixon GL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>doi_14692_jac_dks504</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CF81463F-F628-48AF-908F-2708377B015A</gtr:id><gtr:title>Rational Design, Synthesis, and Biological Evaluation of Heterocyclic Quinolones Targeting the Respiratory Chain of Mycobacterium tuberculosis.</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/76666ef804145a8e573cb6d669ebbac4"><gtr:id>76666ef804145a8e573cb6d669ebbac4</gtr:id><gtr:otherNames>Hong WD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn><gtr:outcomeId>5a2fd83034c210.74046932</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>352EECBF-A3E3-44AC-AD4D-256ABC3392DC</gtr:id><gtr:title>Antitubercular pharmacodynamics of phenothiazines.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e4fbe34e90e642a091101b0d5ce20fd0"><gtr:id>e4fbe34e90e642a091101b0d5ce20fd0</gtr:id><gtr:otherNames>Warman AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>doi_14692_jac_dks483</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1002586</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>